HomeTeva and Samsung Bioepis announce agreement to commercialise two FDA-approved biosimilars in...

Teva and Samsung Bioepis announce agreement to commercialise two FDA-approved biosimilars in the US

Teva Pharmaceutical and Samsung Bioepis have signed a license and commercialisation agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade (infliximab) and Eticovo (etanercept-ykro), a biosimilar to Enbrel (etanercept).

Under the terms of the agreement, Teva will obtain US commercialisation rights to etanercept-ykro at closing, while US commercialisation rights to infliximab-abda will transfer to Teva in Q3 2027.

The timing of Teva’s future US commercialisation of etanercept-ykro will be announced at a later date.

Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the end of 2026.

Under the terms of the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next three years.

Samsung Bioepis may be eligible for additional launch and sales milestones payments. Teva and Samsung Bioepis will share profit from the commercialisation of these products.

The agreement builds on a series of biosimilar collaborations between Teva and Samsung Bioepis.

In 2025, the companies announced a US agreement for Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab).

In 2026, the companies announced two agreements, including one for Opuviz (aflibercept) in Canada and a separate global agreement to licence, develop and commercialise up to six potential biosimilar candidates currently in early-stage development, including biosimilar candidates referencing Fasenra (benralizumab) and Ilaris (canakinumab).

- Advertisment -
- Advertisment -
- Advertisment -

Most Popular

Popular categories